CardioExchange Archive

March 11th, 2013

Hoping for Good Data from Partner II B: Blogging from ACC.13

Megan Coylewright, MD MPH

Walking the walk on TAVR

---

August 6th, 2012

TAVR and the Price of Innovation

Daniel Mark, Richard A. Lange, MD, MBA and L. David Hillis, MD

In an article published in Circulation, Daniel Mark and Robert Mentz of the Duke Clinical Research Institute and University Medical Center examine the economic and policy implications of the recent validation of transcatheter aortic valve replacement (TAVR) in the PARTNER trials. CardioExchange is fortunate and pleased to present Dr. Mark’s responses to questions about his […]

---

June 26th, 2012

Unlikely PARTNERs Support TAVR

Richard A. Lange, MD, MBA

The FDA approval of TAVR and the design of postmarketing surveillance involved a remarkable degree of collaboration and cooperation among the stakeholders. What to do while we wait for data to accumulate?

---

May 8th, 2012

Selections from Richard Lehman’s Literature Review: Week of May 7th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include a comparison of abciximab and manual aspiration thrombectomy in STEMI, the quality of U.S. clinical trials, 2-year data on PARTNER, TAVR in inoperable decompensating stenosis, clopidogrel genetic testing, and strategies to reduce MI mortality.

---

May 2nd, 2012

Real-World Experience with TAVI: Vive la France!

Richard A. Lange, MD, MBA and L. David Hillis, MD

A study of data from FRANCE 2, a prospectively maintained, multicenter registry of the French national experience with transcatheter aortic valve implantation (TAVI), has now been published in the New England Journal of Medicine. The registry captured every TAVI performed at all 34 active centers in France and Monaco; it therefore reflects “real-life” experience with TAVI in patients with […]

---

March 26th, 2012

PARTNER: TAVR Results Appear Durable at 2 Years

Larry Husten, PHD

Two-year results of the influential PARTNER trial provide continued support for the growing acceptance of transcatheter aortic valve replacement (TAVR) in clinical practice. Previously, results of PARTNER at 1 year had demonstrated similar mortality in high-risk patients with aortic stenosis who underwent TAVR or surgery. Now, the 2-year results have been presented at the American College of Cardiology […]

---

November 14th, 2011

Stenosis vs. Stroke: Is Treatment Worth the Risk?

Eiman Jahangir, MD

Several Cardiology Fellows who are attending AHA.11 this week are blogging together on CardioExchange.  The Fellows include Revathi Balakrishnan, Eiman Jahangir, John Ryan (moderator), and Amit Shah. Read the previous post here. Check back often to learn about the biggest buzz in Orlando. On Sunday morning, I feel like the conference has really begun. I am sitting […]

---

November 11th, 2011

Transapical TAVR on the Ropes: Is It Down for the Count?

Richard A. Lange, MD, MBA and L. David Hillis, MD

STACCATO showed more adverse events with transapical transcatheter aortic valve replacement (TAVR) than with aortic valve replacement (AVR) in low risk, elderly patients. In patients with severe, symptomatic aortic stenosis who are believed to have high surgical risk, PARTNER substudy results presented at the AHA show Transapical TAVR provided no increase (and even a possible decrease) in quality […]

---

November 3rd, 2011

FDA Approves TAVR But Remains in the Crosshairs

Richard A. Lange, MD, MBA

I participated in the panel that recommended approval of the Sapien Transcatheter Heart Valve (THV) for patients with inoperable severe aortic stenosis: so-called transaortic valve replacement (TAVR). The recommendation for approval was based on (a) the perceived strength of the results of the PARTNER study; (b) collaboration and support of the Society of Thoracic Surgeons and […]

---

August 31st, 2011

TAVI—When Will It Come to an Operating Theater Near Me?

Stephen Fleet, MD

At the ESC meeting in Paris, Gerhard Schuler from Leipzig reviewed the current indications for Transcatheter Aortic Valve Implantation (TAVI). TAVI is considered appropriate for: Inoperable patients with severe aortic stenosis with a baseline 1-year mortality risk of 50%.  Patients with severe aortic stenosis and a surgical risk of greater than 15%. Valve-in-valve implantation for degenerated bioprosthetic […]

---